CEO/CSO of Progenics Pharmaceuticals Inc. (PGNX, Financial) Paul J Maddon buys 5,000 shares of PGNX on 06/01/2010 at an average price of $4.99 a share.
Progenics Pharmaceuticals Inc. has a market cap of $157.6 million; its shares were traded at around $4.89 with and P/S ratio of 3.2. Progenics Pharmaceuticals Inc. had an annual average earning growth of 5.6% over the past 10 years.
PGNX is in the portfolios of Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC.
Progenics Pharmaceuticals Inc. has a market cap of $157.6 million; its shares were traded at around $4.89 with and P/S ratio of 3.2. Progenics Pharmaceuticals Inc. had an annual average earning growth of 5.6% over the past 10 years.
PGNX is in the portfolios of Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC.
CEO Recent Trades:
- Buy:: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 05/20/2010 at the average price of 4.93, the price of the stock has decreased by 0.81% since.
Directors and Officers Recent Trades:
- Sell:: Sr. VP, Medical Affairs Robert J Israel sold 7,056 shares of PGNX stock on 03/18/2010 at the average price of 5.37, the price of the stock has decreased by 8.94% since.
- Sell:: President Mark Robert Baker sold 2,165 shares of PGNX stock on 03/18/2010 at the average price of 5.33, the price of the stock has decreased by 8.26% since.
